• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Asthma and COPD global research marketplace on the rise

Report: Asthma and COPD global research marketplace on the rise

February 2, 2016
CenterWatch Staff

Asthma and the COPD segment will be significantly driven by the sudden increase in the patient population, according to Allied Market Research.

Asthma is interpreted as a respiratory disorder that affects the airway system of a human body. This chronic disease often turns fatal if left untreated. There are chances that the patient’s conditions can even worsen, resulting in extreme respiratory problems. Although there are several drugs available in the market to treat asthma, the present day drug manufacturers boast of treat the condition effectively and successfully.

The appalling results of asthma drug trials have now become a talking point of all medical conference. These trials are under intense scrutiny than ever. GlaxoSmithKline has provided clarity on its intensions to fill in the growing vacuum in sales. In December 2015, the company received an approval to market the Nucala. The drug works as an add-on treatment for adults combating severe refractory eosinophilic conditions.

The prevention as well as long -term control are effective ways of stopping asthma even before the condition occurs. Long-term control drugs effective in asthma are Theophylline, Leukotriene modifiers, Long-acting beta agonists, Inhaled corticosteroids and Combination inhalers amongst others. On the other hand, the quick relief medications for asthma include Oral and intravenous corticosteroids, Short-acting beta agonists and Ipratropium (Atrovent). Moreover, there is strong demand for allergy medications. These drugs play an important role when the disease is triggered or the condition worsens due to allergies. Such drugs include allergy shots (immunotherapy) and Omalizumab (Xolair).

Asthma drug manufacturers have been seen investing generously on R&D. Last year a U.K.-based biopharmaceutical brand, Atopix Therapeutics, raised funds to advance its key product OC459, effective in treating asthma.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing